A Phase 1, Single- and Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of NLY01 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs NLY 01
- Indications Alzheimer's disease; Parkinson's disease; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Neuraly
- 26 Sep 2019 Status changed from recruiting to completed.
- 21 Sep 2018 Status changed from not yet recruiting to recruiting.
- 13 Sep 2018 Status changed from planning to not yet recruiting.